chr1-155910658-C-G
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PP3_ModeratePP5_Very_Strong
The ENST00000368323.8(RIT1):c.104G>C(p.Ser35Thr) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,230 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
ENST00000368323.8 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RIT1 | NM_006912.6 | c.104G>C | p.Ser35Thr | missense_variant, splice_region_variant | 2/6 | ENST00000368323.8 | NP_008843.1 | |
RIT1 | NM_001256821.2 | c.155G>C | p.Ser52Thr | missense_variant, splice_region_variant | 2/6 | NP_001243750.1 | ||
RIT1 | NM_001256820.2 | c.-2-152G>C | intron_variant | NP_001243749.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RIT1 | ENST00000368323.8 | c.104G>C | p.Ser35Thr | missense_variant, splice_region_variant | 2/6 | 1 | NM_006912.6 | ENSP00000357306 | P3 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152230Hom.: 0 Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152230Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74374
ClinVar
Submissions by phenotype
Noonan syndrome 8 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change replaces serine, which is neutral and polar, with threonine, which is neutral and polar, at codon 35 of the RIT1 protein (p.Ser35Thr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with Noonan syndrome (PMID: 23791108, 25124994, 26714497, 26757980, 27101134). ClinVar contains an entry for this variant (Variation ID: 183401). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects RIT1 function (PMID: 23791108, 27226556). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | May 27, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 16, 2022 | Published functional studies demonstrate S35T results in enhanced ELK1 transactivation and altered GDP/GTP binding activities (Aoki et al., 2013; Fang et al. 2016); Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25049390, 27226556, 25124994, 25959749, 26757980, 26714497, 28666118, 27101134, 30898653, 29595814, 23791108) - |
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Jul 12, 2018 | - - |
Noonan syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 11, 2016 | proposed classification - variant undergoing re-assessment, contact laboratory - |
Pathogenic, no assertion criteria provided | clinical testing | Service de Génétique Moléculaire, Hôpital Robert Debré | - | - - |
RASopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 08, 2023 | Variant summary: RIT1 c.104G>C (p.Ser35Thr) results in a conservative amino acid change located in the Small GTP-binding protein domain (IPR005225) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 251328 control chromosomes (gnomAD). c.104G>C has been reported in the literature in multiple individuals affected with Noonan Syndrome (e.g. Aoki_2013, Bertola_2014, Kouz), including some cases where the variant was confirmed to have arisen de novo (Kouz_2016). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, demonstrating the variant causes gain-of-function, which is a known mechanism of disease (e.g. Fang_2016). The following publications have been ascertained in the context of this evaluation (PMID: 23791108, 25124994, 27226556, 27101134). Five ClinVar submitters have assessed the variant since 2014: all have classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at